Si terrà giovedì 20 marzo prossimo un Convegno Nazionale, organizzato da AboutPharma: “ISF 2014 – Come cambia l’Informazione Medico Scientifica: stato dell’arte e prospettive future" [you see: https://www.fedaiisf.it/Start/HDefault.aspx?Newsid=8894].
Important exponents of the Italian pharmaceutical industry will participate in this conference: Dompè, Doc Generici, Chiesi, Zambon. The FIMMG Secretary of Lombardy, Fiorenzo Corti (fiorenzocorti@fimmglombardia.org).
There will also be someexperts”:
– PAOLO MARIANI, University of Milan Bicocca, Prof. of economic statistics, research on applied Business Statistics and Market Analysis. Phone: 02 6448 5822 paolo.mariani@unimib.it
– Studio Legale LUPI & Associati (vedasi: http://www.impresaediritto.com/wp-content/uploads/2012/02/2007-03_Pubblicita_del_Farmaco.pdf)
– Nessun Informatore Scientifico del Farmaco sarà presente. Questa gente non sa nemmeno che in base al D.Lgs, 219 chi fa il nostro lavoro non si chiama Informatore Medico Scientifico e ovviamente ci definisce “forza vendite”!
The Conference seems very important to us for our future. We recall that in response to Law 219/06 and the Regulation of Scientific Information on Drugs being established, Farmindustria sponsored a similar conference, also organized by About Pharma, on 20 September 2006 in Milan at the Press Club "HOW DOES SCIENTIFIC INFORMATION CHANGE AFTER THE CONSOLIDATED TEXT AND THE REGIONAL REGULATION” (attached, particularly interesting, the report by Drei) which outlined the future scenario of the pharmaceutical market and the change to be imposed on scientific information in the following years. The Union was asleep or perhaps too busy studying the transformation of the ISF in a commercial sense, in order to be able to protect it better, it did not realize that in that congress there was the declaration of everything they would have done to distort the market and lay off that huge mass of ISF, first of all the disappearance or drastic reduction of primary care. We ourselves took the matter lightly and did not evaluate the tragic consequences of that conference. We have the impression that this time we want to make the decisive commercial breakthrough for our business. Is scientific information finished? Let's hope we're wrong.